Valuation: Rein Therapeutics Inc.

Capitalization 52.86M 50.45M 47.61M 41.91M 74.97M 4.59B 83.02M 566M 210M 1.92B 198M 194M 8B P/E ratio 2024 *
-1.82x
P/E ratio 2025 * -1.72x
Enterprise value 52.86M 50.45M 47.61M 41.91M 74.97M 4.59B 83.02M 566M 210M 1.92B 198M 194M 8B EV / Sales 2024 *
-
EV / Sales 2025 * -
Free-Float
99.35%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart

Last Transcript: Rein Therapeutics Inc.

1 day+3.83%
1 week+8.44%
Current month+23.86%
1 month+22.00%
3 months-14.98%
6 months+29.10%
Current year+6.09%
More quotes
1 week
2.15
Extreme 2.15
2.50
1 month
1.88
Extreme 1.88
3.50
Current year
1.84
Extreme 1.8396
3.50
1 year
1.61
Extreme 1.61
7.42
3 years
1.01
Extreme 1.01
15.00
5 years
1.01
Extreme 1.01
49.40
10 years
1.01
Extreme 1.01
309.60
More quotes
Manager TitleAgeSince
Chief Executive Officer 59 2024-03-10
Director of Finance/CFO 63 2024-05-15
Chief Tech/Sci/R&D Officer 52 2018-11-04
Director TitleAgeSince
Director/Board Member 69 2013-05-31
Director/Board Member 55 2018-09-05
Chairman 70 2023-10-30
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
+3.83%+8.44%-47.97%-71.12% 52.86M
-0.77%-2.33%+8.72%+97.19% 118B
-0.10%-2.43%-28.95%+7.48% 72.09B
+1.12%-2.75%+70.11%+143.60% 39.13B
-2.40%+3.96%+30.72%-23.85% 28.73B
+2.38%+5.09%+55.74%+12.51% 24.63B
+4.77%+6.35%+17.32%-36.67% 24.62B
-2.06%+4.24%+321.50%+968.50% 15.76B
+0.81%+1.52%+168.76%+237.20% 14.19B
+0.37%+8.99%-19.60%-31.36% 13.48B
Average +0.80%+3.81%+57.63%+130.35% 35.06B
Weighted average by Cap. +0.11%-0.50%+32.98%+98.52%
See all sector performances

Financials

2024 *2025 *
Net sales - -
Net income -24.5M -23.38M -22.07M -19.42M -34.74M -2.13B -38.48M -262M -97.18M -888M -91.82M -90M -3.71B -36.39M -34.73M -32.78M -28.85M -51.61M -3.16B -57.16M -389M -144M -1.32B -136M -134M -5.51B
Net Debt - -
More financial data * Estimated data
Logo Rein Therapeutics Inc.
Rein Therapeutics, Inc., formerly Aileron Therapeutics, Inc., is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. The Company's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).
Employees
15
More about the company
Date Price Change Volume
25-02-14 2.440 $ +3.83% 35,120
25-02-13 2.350 $ +2.17% 23,110
25-02-12 2.300 $ +7.98% 31,287
25-02-11 2.130 $ -5.33% 32,196

Delayed Quote Nasdaq, February 14, 2025 at 04:00 pm EST

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.440USD
Average target price
13.00USD
Spread / Average Target
+432.79%
Consensus

Quarterly revenue - Rate of surprise